MARKET COMPOSITE
NMRD - Nemaura Medical Inc
Price
$0.00
+ 0.00 (0.00%)
Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. The company was founded by Dr Faz Chowdhury in 2013. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. It is headquartered in Loughborough, United Kingdom. It developed SugarBEAT, a disposable skin-patch thats sticks to the body using a non-irritant soft silicone gel. The skin-patch connects to a rechargeable transmitter which detects blood sugar and transfers the data to a mobile app at a 5 minute interval. The lifespan of the transmitter is 2 years and the skin patch can be used for 24 hours. The skin patch has an approximate thickness of 1mm. Electronic currents are used to draw interstitial fluid to the surface which analyses the glucose level.
Financials
Quarterly financials
(USD)Sep 2023Q/Q
Revenue0-
Gross Profit0-
Cost Of Revenue--
Operating Income-2.1MM+12%
Operating Expenses2.1MM-0%
Net Income-1.2MM-54%
R&D491.8K-11%
G&A1.6MM+3%
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take place on Wednesday, January 24th, & Thursday, January 25th, 2024, starting at 9:00 a.m. ET. We will be presenting our 2024 Healthcare IT Virtual Conference. Allen Klee, Senior Research Analyst at Maxim Grou

    Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical’s Board of Directors and management team have made the strategic decision t

    Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing

    Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medi

    The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

    Nemaura Medical ( NASDAQ:NMRD ) First Half 2024 Results Key Financial Results Net loss: US$3.81m (loss narrowed by 52...

    NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

    Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical int

    Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update. Corporate Highlights: 1.The Company continued to support its UK licensee with its endeavours t

    LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their